Theravance Reports Positive New Data from Multiple Studies of Anti-infective

Data from TOUR™ Observational Patient Registry Demonstrate 77.1% Clinical Response Rate for VIBATIV® (telavancin) in Patients with Monomicrobial Staphylococcus aureus Infections with Vancomycin MIC ≥ 1 µg/mL
Additional TOUR Data Demonstrate Unchanged Renal Function in 68.7% of Patients Who Received VIBATIV Treatment for More Than 21 Days and Had CrCl Measured at Baseline and End of Treatment   

Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today announced that positive new data from multiple studies of VIBATIV^® (telavancin) were presented at IDWeek^™ 2018, which was held in San Francisco, CA, on October 3 – 7, 2018. Two presentations were made reporting new data from the ongoing Telavancin Observational Use Registry (TOUR^™) study, which is designed to report how VIBATIV^® (telavancin) is being used by healthcare practitioners to treat patients in real-world clinical settings. Presented findings from one study reported a positive clinical response following VIBATIV treatment in 77.1% of registry patients diagnosed with monomicrobial infections caused by Staphylococcus aureus (S. aureus) with vancomycin minimum inhibitory concentration (MIC) ≥ 1 µg/mL. Positive clinical response was defined as cure or improvement leading to step-down oral therapy. Results from a second study demonstrated that renal function was unchanged in 68.7% of TOUR patients who received treatment with VIBATIV for more than 21 days and had creatinine clearance (CrCl) measured at baseline and end of treatment.

https://www.biospace.com/article/releases/theravance-biopharma-reports-positive-new-data-from-multiple-studies-of-vibativ-telavancin-at-idweek-2018/